Durable Antitumor Activity in ccRCC With Combination Belzuti

“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.

Related Keywords

Spain , Madrid , France , Massachusetts , United States , Dana Farber Cancer Institute , Paris , France General , Boston , Nat Genet , Tonik Choueiri , Genitourinary Oncology Disease Center , European Society For Medical Oncology , Harvard Medical School , Lank Center , European Society Of Medical Oncology , International Metastatic , Database Consortium , Medical Oncology , Annual Congress , Genitourinary Oncology , European Society , Esmo 2023 , Nrcc , Nccrcc , Clear Cell Rcc , Clear Cell Renal Carcinoma , Kidney Cancer ,